血清糖基化纤连蛋白预测新发高血压孕妇即将发生的子痫前期
前瞻性观察研究纳入409例24-41周妊娠新发高血压单胎孕妇,比较血清糖基化纤连蛋白(GlyFn)、胎盘生长因子(PlGF)及sFlt-1/PlGF比值预测2周内因子痫前期(PE)分娩的效能;GlyFn与sFlt-1/PlGF检出率均为62.4%,PlGF为60.2%,但所有检测预测效能相对较差。
要点
- 血清GlyFn预测2周内因PE分娩的检出率与sFlt-1/PlGF比值相似(均为62.4%),PlGF为60.2%。
- GlyFn筛查阳性率与sFlt-1/PlGF比值>85相同(46.2%),对应GlyFn阈值为510 µg/mL。
- 所有检测在≥38周妊娠时预测效能更差,检出率47-63%(筛查阳性率40-50%)。
核心结论
- 在新发高血压孕妇中,血清GlyFn预测2周内因PE分娩的效能与PlGF及sFlt-1/PlGF比值相似,但GlyFn可能因快速床旁检测而成为首选;然而所有检测的预测效能相对较差。
研究设计与样本
- 前瞻性观察研究,纳入409例24-41周妊娠新发高血压单胎孕妇,比较血清GlyFn、PlGF及sFlt-1/PlGF比值的预测效能;sFlt-1/PlGF比值推荐截断值为85,GlyFn和PlGF截断值设定为与sFlt-1/PlGF比值>85相同的筛查阳性率(46.2%)。
诊断标准与关键数值
- sFlt-1/PlGF比值>85筛查阳性率为46.2%;匹配该筛查阳性率时PlGF截断值为75 pg/mL、GlyFn截断值为510 µg/mL;2周内因PE分娩总体检出率:GlyFn和sFlt-1/PlGF均为62.4%(95% CI 51.7-72.2%),PlGF为60.2%(95% CI 49.5-70.2%)。
临床应用与阅片要点
- 作者认为GlyFn可能因快速床旁检测而成为首选;所有检测在≥38周妊娠时预测效能更差,检出率47-63%(筛查阳性率40-50%)。
局限性
- 所有检测的预测效能相对较差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the predictive performance for delivery with pre-eclampsia (PE) within 2 weeks after assessment in women with new-onset hypertension at 24-41 weeks' gestation between serum glycosylated fibronectin (GlyFn) concentration, serum placental growth factor (PlGF) concentration and soluble fms-like tyrosine kinase-1 (sFlt-1) to PlGF concentration ratio.
METHODS: This was a prospective observational study of 409 women with a singleton pregnancy presenting at 24-41 weeks' gestation with new-onset hypertension. The recommended cut-off for sFlt-1/PlGF ratio for the prediction of PE in the platform used in this study is 85; the appropriate cut-offs for GlyFn and PlGF were determined to achieve the same screen-positive rate as that of sFlt-1/PlGF ratio > 85. We then compared the predictive performance for delivery with PE within 2 weeks after presentation between GlyFn, PlGF and sFlt-1/PlGF, both overall and in subgroups according to gestational age at presentation.
RESULTS: Delivery with PE within 2 weeks occurred in 93 (22.7%) cases. The screen-positive rate for sFlt-1/PlGF ratio > 85 was 46.2%. The cut-off corresponding to a screen-positive rate of 46.2% was 75 pg/mL for PlGF and 510 µg/mL for GlyFn. The overall detection rate for delivery with PE within 2 weeks after presentation was 62.4% (95% CI, 51.7-72.2%) for GlyFn and sFlt-1/PlGF and 60.2% (95% CI, 49.5-70.2%) for PlGF. In all women who delivered with PE within 2 weeks after presentation at < 34 weeks' gestation and in about 60-70% of those presenting at < 38 weeks, GlyFn and sFlt-1/PlGF were increased and PlGF was reduced. However, the screen-positive rate for these tests was very high at about 45%. The predictive performance for delivery with PE within 2 weeks after presentation at ≥ 38 weeks' gestation was poorer for all three methods of screening, with detection rates of 47-63% at screen-positive rates of 40-50%.
CONCLUSIONS: In women with new-onset hypertension, the predictive performance for delivery with PE within 2 weeks after presentation for serum GlyFn is similar to that of PlGF and the sFlt-1/PlGF ratio, but GlyFn may be the preferred option because it is a rapid point-of-care test. However, the predictive performance for all tests is relatively poor. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Sokratous N, Bednorz M, Wright A, et al. Prediction using serum glycosylated fibronectin of imminent pre-eclampsia in women with new-onset hypertension. Ultrasound Obstet Gynecol. 2023. PMID: 37606310. doi:10.1002/uog.27458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。